WILMINGTON, Del., Dec. 05, 2016 -- Andrews & Springer LLC, a boutique securities class action law firm focused on representing shareholders nationwide, is investigating potential securities violation and breach of fiduciary duty claims against the Board of Directors of Immunomedics, Inc. (“Immunomedics” or the “Company”).
If you own shares of Immunomedics and want to receive additional information and protect your investments free of charge, please visit us at http://www.andrewsspringer.com/cases-investigations/immunomedics-class-action-investigation/ or contact Craig J. Springer, Esq. at [email protected], or call toll free at 1-800-423-6013. You may also follow us on LinkedIn – https://www.linkedin.com/company/andrews-&-springer-llc , Twitter – www.twitter.com/AndrewsSpringer or Facebook - www.facebook.com/AndrewsSpringer for future updates.
Andrews & Springer is a boutique securities class action law firm representing shareholders nationwide who are victims of securities fraud, breaches of fiduciary duty or corporate misconduct. Having formerly defended some of the largest financial institutions in the world, our founding members use their valuable knowledge, experience, and superior skill for the sole purpose of achieving positive results for investors. These traits are the hallmarks of our innovative approach to each case our Firm decides to prosecute. For more information please visit our website at www.andrewsspringer.com. This notice may constitute Attorney Advertising.
Contact: Craig J. Springer, Esq. [email protected] Call Toll Free: 1-800-423-6013


Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift 



